Valeant in talks to buy Actavis for over $13 billion: WSJ
(Reuters) - Canada's biggest listed drug maker, Valeant Pharmaceuticals International Inc (VRX.TO), is in talks to buy generic drugmaker Actavis Inc (ACT.N) for more than $13 billion, Wall Street Journal reported, citing people familiar with the matter.
The companies had been working towards an all-stock deal, when some of Actavis' directors came out against it around the middle of this week. But executives on the two sides are still working to resurrect the deal, the journal said.
Valeant said in February it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals."
Shares of Actavis, which has a market capitalization of $12.9 billion, have risen about 12 percent in the past three months.
Actavis, the third-largest global generic drugmaker, changed its name in January from Watson after buying Actavis as part of its strategy to expand in international markets and offer more specialty drugs.
Valeant and Actavis could not be immediately reached for comments outside of business hours.
(Reporting by Neha Alawadhi in Bangalore; Editing by Bernard Orr)
DETROIT - General Motors Co reported a much lower second-quarter profit on Thursday due to numerous recalls and the expected cost of at least $400 million for a compensation fund for those killed or injured by a defective ignition switch linked to at least 13 deaths.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.